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Abstract
Background: Bacterial toxins have evolved to an effective therapeutic option for cancer therapy. The Clostridium
perfringens enterotoxin (CPE) is a pore-forming toxin with selective cytotoxicity. The transmembrane tight junction
proteins claudin-3 and -4 are known high affinity CPE receptors. Their expression is highly upregulated in human
cancers, including breast, ovarian and colon carcinoma. CPE binding to claudins triggers membrane pore complex
formation, which leads to rapid cell death. Previous studies demonstrated the anti-tumoral effect of treatment with
recombinant CPE-protein. Our approach aimed at evaluation of a selective and targeted cancer gene therapy of
claudin-3- and/or claudin-4- expressing colon carcinoma in vitro and in vivo by using translation optimized CPE
expressing vector.
Methods: In this study the recombinant CPE and a translation optimized CPE expressing vector (optCPE) was used
for targeted gene therapy of claudin-3 and/or -4 overexpressing colon cancer cell lines. All experiments were
performed in the human SW480, SW620, HCT116, CaCo-2 and HT-29 colon cancer and the isogenic Sk-Mel5 and
Sk-Mel5 Cldn-3-YFP melanoma cell lines. Claudin expression analysis was done at protein and mRNA level, which
was confirmed by immunohistochemistry. The CPE induced cytotoxicity was analyzed by the MTT cytotoxicity assay.
In addition patient derived colon carcinoma xenografts (PDX) were characterized and used for the intratumoral in
vivo gene transfer of the optCPE expressing vector in PDX bearing nude mice.
Results: Claudin-3 and -4 overexpressing colon carcinoma lines showed high sensitivity towards both recCPE
application and optCPE gene transfer. The positive correlation between CPE cytotoxicity and level of claudin
expression was demonstrated. Transfection of optCPE led to targeted, rapid cytotoxic effects such as membrane
disruption and necrosis in claudin overexpressing cells. The intratumoral optCPE in vivo gene transfer led to tumor
growth inhibition in colon carcinoma PDX bearing mice in association with massive necrosis due to the
intratumoral optCPE expression.
Conclusions: This novel approach demonstrates that optCPE gene transfer represents a promising and efficient
therapeutic option for a targeted suicide gene therapy of claudin-3 and/or claudin-4 overexpressing colon
carcinomas, leading to rapid and effective tumor cell killing in vitro and in vivo.
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Background
The incidence of colorectal cancer is increasing and is as-
sociated with the fourth highest cancer associated mortality
rate worldwide [1, 2]. Despite advances in chemotherapy,
radiotherapy and the development of new drugs, the prog-
nosis for patients remains poor. Therefore, new targets and
therapeutic substances are desperately needed [3, 4].
One promising strategy may be targeted suicidal can-
cer gene therapy, including an approach by which for-
eign toxic molecules are specifically delivered to tumor
cells [5, 6]. Attractive candidates include bacterial toxins,
which have demonstrated efficient cell-killing capacity in
several in vitro and in vivo studies [7–10]. Pore-forming
bacterial toxins, such as streptolysin O (Streptococcus
pyrogenes) and Clostridium perfringes enterotoxin (CPE),
are of particular interest [11–14].
Strain A Clostridium perfringens, an anaerobic gram-
positive bacterium, produces the CPE protein, associated
mainly with food poisoning [15, 16]. The protein binds
claudin-4 and claudin-3 on targeted cells [17, 18]. The
claudin family consists of at least 27 proteins that are es-
sential for tight-junction formation in epithelial and
endothelial cells and are important in controlling para-
cellular transport and the maintenance of cell polarity
[19–23]. The binding of CPE to claudins triggers the for-
mation of a multi-protein membrane pore complex,
leading to a loss of cellular osmotic equilibrium and
rapid cell lysis [24, 25]. Cells that lack claudin-3 or -4
expression are unaffected by the toxin [11, 17]. Numer-
ous studies have shown that colon carcinoma and other
epithelial tumors exhibit increased claudin-3 and/or -4
expression, suggesting that CPE might selectively target
such tumors [26–37]. In our previous study we reported
the successful tumor targeted in vitro and in vivo suicide
gene therapy [11]. Based on this, the present approach is
employing CPE gene therapy to selectively eradicate
claudin-3 and -4 expressing colon carcinomas as a new
strategy for this tumor entity.
Here, we use in vitro and in vivo approaches to dem-
onstrate that claudin-3 and -4 expressing human colon
cancers can be successfully treated by CPE gene transfer.
CPE expression in these cells permits a rapid and select-
ive eradication of colon cancer, further enhanced by a
toxin-mediated bystander effect. We show that CPE spe-
cifically binds to the claudins in these cells and provide
data on the kinetics of cytotoxicity as well as intracellu-
lar distribution of CPE after gene transfer. Our study re-
veals that CPE gene therapy can be used for the
successful treatment of colon cancer.
Methods
Cell lines
Human SW480, SW620, HCT116 colon carcinoma and
isogenic Sk-Mel5 and Sk-Mel5 Cldn-3-YFP melanoma
cell lines were grown in RPMI medium (Gibco, Life
technologies, Darmstadt, Germany), 10% FCS (Bio-
chrom, Berlin,Germany). The colon carcinoma lines
CaCo-2 and HT-29 were grown in DMEM (Gibco), 10%
FCS (Biochrom). All lines were kept at 37 °C, 5% CO2.
Claudin-3-YFP stably transfected cells were selected with
0.5–1.5 mgml-1 G418 (Gibco). The expression vector for
Cldn-3-YFP is based on pEYFP-N1 [9]. The identity of
all cell lines was confirmed by STR-genotyping (DSMZ,
Braunschweig, Germany).
Quantitative real-time RT-PCR
Cell lysis and isolation of total RNA was done using
GeneMatrix Universal RNA Purification Kit EURx
(Roboklon, Berlin, Germany). 50 ng of RNA was reverse
transcribed and real-time RT-PCR (qRT-PCR) was per-
formed with SYBR GREEN. Each real-time PCR (qPCR)
was done using the LightCycler 480 (Roche Diagnostics,
Mannheim, Germany). Following primers were used for
claudin-3: forward 5’-CTGCTCTGCTGCTCGTGTCC-
3’; reverse 5’-TTAGACGTAGTCCTTGCGGTCGTAG-
3’; for claudin-4: forward 5’-CCTCTGCCAGACCCATA
TAA-3’; reverse 5’-CACCGTGAGTCAGGAGATAA-3’.
The cycle conditions were as follows: 90 °C for 30 s, 95 °C
for 5 s, 57 °C for 5 s and 72 °C for 10 s for 45 cycles.
Normalization was done with the human housekeeping
gene glucose-6-phosphate dehydrogenase (hG6PDH)
using the hG6PDH Roche Kit (Roche Diagnostics).
Western Blot
For protein analysis, cells or tissue cryosections were
lysed in RIPA buffer (50 mM TRIS, 150 mM, NaCl, 1%
Nonidet P-40, 0.5% sodium deoxycholate, protease in-
hibitor, ddH2O) and 25 μg of protein was electrophor-
ezed in 10% precast NuPAGE gels (Invitrogen), 1 h at
180 V. The proteins were transferred to nitrocellulose
membranes (Hybond-C Extra, Amersham, Freiburg,
Germany) by semidry blotting (Turbo Blot BioRad,
Munich, Germany) at 20 V, 25 min. Membranes were
blocked for 1 h at room temperature (RT) in TBS (50 mM
Tris, 150 mM NaCl, pH 7.5, 5% fat-free dry milk and 2.5%
casein) and washed in TBST (0.05% Tween 20 in PBS), 2 x
5 min at RT. As primary antibody rabbit anti-claudin-3
antibody (1:3000, Acris, Herford, Germany), rabbit anti-
claudin-4 antibody (1:3000, Acris), rabbit anti-CPE (1:4000,
Acris), mouse monoclonal anti-β-tubulin (1:1000, BD Bio-
science, MD, USA) or mouse monoclonal anti-β-actin anti-
body (1:10000, Sigma-Aldrich, MI, USA) was added
respectively over night at 4 °C and washed in TBST. As
secondary HRP-labeled goat anti-rabbit-IgG antibody
(1:10000, Promega, Madison, WI, USA) or goat anti-
mouse IgM/IgG (1:10000, Sigma-Aldrich) was added for
1 h, RT. Membranes were washed in TBST. Detection was
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done using ECL solution (Amersham) and exposure to
Kodak X-Omat AR film (Kodak, Stuttgart, Germany).
Clostridium perfringens enterotoxin (CPE) expressing
plasmids
For transfection experiments the pCpG-optCPE (optCPE)
plasmid was used [11]. For construction of plasmid encod-
ing optCPE-GFP fusion protein, cDNA of CPE was ampli-
fied by PCR from optCPE and cloned into the Pst I site of
pcDNA3.1/CT-GFP (GFP Fusion TOPO TA Expression
Kit, Invitrogen Life Technology) resulting in pcDNA3-
optCPE-GFP (optCPE-GFP). Preparation of plasmid-DNA
was done using the Jetstar Plasmid Purification Maxi
Kit (Genomed, Löhre, Germany).
Transfection of human tumor cell lines
Cells were seeded into 6-well plates and transfected
with 1.75–3.5 μg DNA (pCpG-optCPE, pCpG-mcsG2/
pcDNA3.1 as empty vector or pcDNA3-optCPE-GFP fu-
sion protein vector) using the transfection reagents
Fugene X-treme (Roche), Fugene HD (Roche) or
Metafectene (Biontex) as recommended by the manu-
facturer. To ensure comparable transfection rates,
transfection efficiency for each cell line was deter-
mined by transfection of green fluorescent protein ex-
pressing plasmid pEGFP-N1 (Clontech, Mountain View,
CA, USA) and analyzed using FACS Calibur (Becton
Dickinson, San Jose, CA, USA). The number of green
fluorescence protein expressing cells was quantified
48 h after transfection and given as a percentage of
green fluorescent protein positive cells.
RNAi
For knock-down experiments cells were seeded in 6-well
plates and transfected with 50 nM siRNA control, siRNA
Claudin-3 (iBONi siRNA box Cldn3 gene ID1363,
Riboxx, Germany) or siRNA Claudin-4 (iBONi siRNA
box Cldn4 gene ID1364, Riboxx, Germany) using Lipo-
fectamine RNAiMax Reagent (Thermo Fisher Scientific,
Darmstadt, Germany) according to the manufacturer’s
instructions. Cells were seeded for recCPE treatment or
optCPE gene transfer 48 h after siRNA transfection.
MTT cytotoxicity assay
MTT assay was performed to test cytotoxicity of recom-
binant CPE or after optCPE transfection and biological
activity of released CPE from transfected cells. For sensi-
tivity testing of the cell lines towards recombinant CPE
6 × 103- 4 × 105 cells were seeded into 96-well plates
and 24 h later the toxin was added at different concen-
trations (0, 50, 100, 150 ng ml-1) and incubated for 72 h.
For determination of the biological activity of CPE in
supernatants of transfected cells, 6 × 103 non-
transfected cells were seeded into 96-well plates. After
24 h, 100 μl of supernatants from optCPE transfected
cells were added to the respective non-transfected cells
and incubated for 72 h. For all cytotoxicity assays
MTT (3-(4,5-dimethylthiazyol-2yl)-2,5-diphenyltetrazolium
bromide (5 mg ml-1, Sigma) was added after 72 h of CPE
incubation and absorbance was measured in triplicates at
560 nm in a microplate reader (Tecan, Groedig, Austria).
Values are expressed as percentage of untreated controls.
CPE ELISA
Ridascreen Clostridium perfringens Enterotoxin ELISA
(R-Biopharm, Darmstadt, Germany) was performed to
quantify CPE in supernatants 24 h or 48 h after transfec-
tion. For this, 4 × 105 cells were seeded into 6-well plates
and transfected with pCpG-optCPE or pCpG-mscG2 (e.v.)
plasmid-DNA. Supernatants were used for the detection
as recommended by the manufacturer. For analyzing po-
tential shedding of CPE into the blood of animals, which
received gene transfer, blood was collected and CPE was
quantified in serum samples. Recombinant CPE was used
as standard at serial dilutions of 0.4 ng to 25 ng CPE ml-1.
Measurements were done in duplicates at 450 nm in the
microplate reader (Tecan). Values are expressed as per-
centage of untreated controls.
Immunofluorescence and immunohistochemistry
For immunofluorescence, 2 × 105 cells were seeded onto
cover slips (Steiner GmbH, Siegen Eiserfeld, Germany).
After 24 h cells were treated with Hoechst 33342 (5 μM)
or recombinant CPE (250 ng ml-1, R-Biopharm) or were
transfected with pcDNA3.1 as empty vector, pCpG-
optCPE (optCPE) or pcDNA3-optCPE-GFP (optCPE-
GFP) as described. Cells were washed with PBS, fixed
15 min in 3.7% (v/v) formaldehyde in PBS, quenched
20 min with 0.1 M glycin in PBS and blocked 1 h with
1% (w/v) bovine serum albumin and 0.05% Tween 20 in
PBS at RT. As primary antibody, rabbit anti-human
claudin-3 or rabbit anti- human claudin-4 antibody
(1:100, Acris) or rabbit anti-CPE (1:1000, Acris) was
added for 2 h at RT. Cells were washed with TBST.
Alexa 488 labeled goat anti-rabbit-IgG (1:1000, Invitro-
gen) or Alexa 555 labeled goat anti-rabbit-IgG (1:1000,
Invitrogen) was added as secondary antibody for 1 h at
RT. For staining of nuclei DAPI (Sigma-Aldrich) and for
staining of the cytoplasm Alexa 555 phalloidin (Thermo
Fisher Scientific) was used. Cells were evaluated in a
fluorescence microscope (Zeiss, Jena, Germany).
For immunohistochemistry of the patient-derived
xenotransplant (PDX, EPO GmbH, Berlin, Germany)
tumor samples 3–5 μm paraffin embedded tumor
sections were deparaffinized, fixed with 0.04% glutaral-
dehyde for 15 min at RT, quenched 20 min with 0.1 M
glycin, incubated 10 min with 3% H2O2, washed with
PBS, permeabilized by 0.2% Triton X-100 in PBS for
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10 min, RT and blocked 1 h with 1% (w/v) bovine serum
albumin and 0.05% Tween 20 in PBS at RT. Primary
antibody rabbit anti-human claudin-3/-4 (1:200, Acris)
was added for 2 h, RT. Sections were washed with PBS
and as secondary antibody HRP-labeled goat anti-rabbit
antibody (1:200, Promega) was added for 1 h, RT, then
washed in PBS and incubated with diamino-benzidine
(DAB, DAKO, Hamburg, Germany) 1 min, at RT, washed
in PBS, counterstained for 30 s with hemalum (Roth,
Karlsruhe, Germany), rinsed in water, covered with glycer-
gel (DAKO) and evaluated in a light microscope (Zeiss).
in vivo optCPE gene transfer
For establishment of subcutaneous tumors, pieces of
app. 3 × 3 mm in size of patient derived colorectal can-
cer xenograft tissue (PDX, Co7515*, lung metastasis of
colon cancer, see Additional file 1) were inoclulated into
the left flank of female NMRI: nu/nu mice (n = 5 animals
per group). When tumors reached a mean volume of
0.3 cm3, animals were randomized into treatment
groups. Intratumoral non-viral optCPE gene transfer was
performed in anesthetized animals by jet-injection.
Therefore, 50 μg plasmid DNA of respective vector con-
struct was applied by 5 injections (jet injector, EMS
Medical Systems SA, Nyon, Switzerland) of 10 μl injec-
tion volume (1 μg DNA μl-1 PBS). The in vivo optCPE
gene transfer gene transfer was performed once at day
46 post tumor inoculation.
Tumor volumes (TV) were measured at indicated time
points and calculated using the formula: TV = (width2 x
length)/2. As toxicity parameters body weight, clinical
signs and behavior were recorded for all mice twice a
week. Animals were sacrificed and tumors were har-
vested for further analysis.
Statistical analysis
For statistical analyses of the in vitro experiments
the Student’s t-test, 1way-ANOVA test and 2way-
ANOVA test was used. For the analyses of in vivo
optCPE gene transfer experiments the non-
parametric Mann-Whitney test was used. Error
values for the in vitro experiments are S.D. and for
in vivo optCPE gene transfer experiment S.E.M.
Results
Claudin-3 and -4 expression in human colon carcinoma
cell lines
CPE toxicity is dependent on the presence of claudin-3
and -4. Therefore, we tested human colon carcinoma
cell lines HT-29, SW480, SW620, HCT116 and CaCo-2
and the human melanoma cell line Sk-Mel5 for claudin
expression. We found a high expression of claudin-3
and -4 in HT-29 cells at protein- and mRNA-level.
SW620 and HCT116 cells revealed a lower claudin-3
and -4 expression, whereas SW480 and CaCo-2 cells
expressed claudin-4 at a lower level (Fig. 1a). The melan-
oma line Sk-Mel5 was negative for claudin-3 and -4 ex-
pression and was used as negative control in all in vitro
experiments.
Sensitivity of human colon carcinoma cells towards
recombinant CPE
The cell lines HT-29, SW480, SW620, HCT116, CaCo-2
and Sk-Mel5 were treated with recombinant CPE
(recCPE) for sensitivity testing. The treatment revealed a
strong correlation between claudin-3 and -4 expression
and sensitivity towards recCPE (Fig. 1b). The high
claudin-3 and -4 expressing cell line HT-29 showed
highest sensitivity to recCPE with 88% toxicity at a con-
centration of 50 ng ml-1, supported by the low EC50
value of 26.1 ng CPE ml-1 (Table 1). CaCo-2 cells were
less sensitive than HT-29, but still showed a low EC50
value of 54 ng CPE ml-1 compared to the other colon
carcinoma cells. Although HCT116, SW620 and SW480
cells have comparable claudin-3 and -4 expression, these
cells were less sensitive to the recCPE treatment, reflected
by EC50 values of about 100 ng ml
-1. However, concentra-
tion of 150 ng CPE ml-1 was sufficient to kill 80-90% of
these cells. By contrast, the claudin-negative Sk-Mel5 cells
were insensitive towards the toxin, supporting that CPE
toxicity is restricted to claudin-3 and -4 expressing cells.
In vitro CPE expression and selective cytotoxicity after
CPE gene transfer
To evaluate the therapeutic potential of CPE gene transfer
HT-29, HCT116, SW480, SW620, CaCo-2 and Sk-Mel5
cells were transfected with either the optimized pCpG-
optCPE expressing vector (optCPE) or the pCpG empty
vector (e.v.). Cytotoxicity was determined 24 h, 48 h and
72 h after transfection by MTT assay. The experiments
showed high toxicity of optCPE expressing vector in all
claudin-positive cells 48 h after transfection with toxicity
rates of 76–92% (Fig. 2a). In HT-29 and CaCo-2 cells
optCPE exerted 70–87% cytotoxicity as soon as 24 h after
transfection. In SW480, SW620 and HCT116 cells how-
ever, significant (P < 0.001) reduction of cell viability was
detectable after 48 h. By contrast, optCPE transfection did
not have any impact on the claudin-negative melanoma
Sk-Mel5 cells, indicating strict claudin-selectivity of CPE
after gene transfer.
These data further support the correlation between
claudin-3 and -4 expression and CPE mediated toxicity.
Bystander effect of CPE gene transfer
The transfection experiments revealed a much higher
CPE toxicity than it would have been anticipated by trans-
fection rates of 35–75% for the cell lines (Table 2). The by-
stander effect, which is mediated by released optCPE,
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could explain why also non-transfected colon carcinoma
cells are affected after treatment. To prove this, we ana-
lyzed the medium of optCPE transfected cells. Western
blot analysis (Fig. 2b) and quantification by CPE-ELISA
(Table 3) confirmed the presence of optCPE in the
medium 48 h after transfection, ranging from up to
5.4 ng ml-1 released CPE by HT-29 cells to up to
231.67 ng ml-1 CPE liberated by HCT116 cells. The bio-
logical activity of released CPE was tested by adding the
medium, collected 48 h after transfection, to respective
non-transfected cells (Fig. 2c). The cytotoxicity assay
showed up to >90% toxicity in HCT116, SW480 and
SW620 cells and about 76% in CaCo-2 cells, with no effect
on claudin-3 and -4 negative Sk-Mel5 cells. However,
Fig. 1 Expression analysis and sensitivity testing of human colon carcinoma cell lines. Colon cancer cell line HT-29, SW480, SW620, HCT116 and
CaCo-2 and human melanoma cell line Sk-Mel5 were characterized. a Quantitative real-time RT-PCR and western blot for claudin-3 (left) and
claudin-4 expression (right), revealing high claudin-3 and -4 expression in HT-29 and HCT116, mediate claudin-3 expression in SW480 and SW620
and a strong claudin-3 expression in CaCo-2 and no claudin-3 or -4 expression in Sk-Mel5 cells. Columns: mean of triplicates, bars: SD. b Cell sensitivity
toward recombinant CPE protein. Tumor cells were treated at indicated concentrations for 72 h. The cytotoxicity was determined by MTT assay and
compared to untreated control. Strong cytotoxic effects were seen in all colon cancer cells. Claudin-negative cell line Sk-Mel5 was unaffected and used
as negative control. All assays were performed in three independent experiments and expressed as mean percent of untreated control. Bars: SD. Level
of significance was calculated by Student’s t-test; * P < 0.05, **; P < 0.001, *** P < 0.0001
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addition of optCPE containing medium to respective HT-
29 cells only caused minor toxicity, due to the single appli-
cation of CPE at low concentration of only 5 ng CPE ml-1.
For a better mimesis of the conditions achieved by gene
transfer, this medium was added twice a day to respective
non-transfected HT-29 cells (Fig. 2d), since in transfected
HT-29 cells much higher toxicity was seen. This demon-
strated that repeated application, even at low CPE concen-
trations, is sufficient to achieve cytotoxicity, which is
comparable to optCPE-transfected HT-29 cells (Fig. 2a).
These data again support the efficiency of optCPE gene
therapy by prolonged presence of the toxin and the associ-
ated bystander effect for colon cancer eradication.
Claudin-specificity and analysis of claudin-3/optCPE-GFP
co-localization
To elucidate claudin-specificity of CPE activity, the
optCPE-GFP fusion protein was used for treatment of
an isogenic pair of claudin-3 negative and claudin-3
positive Sk-Mel5 cells. They were generated by transfec-
tion of the claudin-3-YFP (Cldn-3-YFP) expressing vector.
The Cldn-3-YFP expression in Sk-Mel5 cells and mem-
branous localization was verified by Western blot analysis
and fluorescence microscopy (Fig. 3a, b). Both show dis-
tinct membranous localization of claudin-3, notably
within cell-cell-contact regions. The isogenic pair was first
treated with recCPE for 72 h (3.125–150 ng CPE ml-1),
leading to >90% cytotoxicity in claudin-3 expressing
Sk-Mel5 cells, whereas the claudin-3 negative cells
remained insensitive (Fig. 3c). For further validation of
claudin-specificity, cells were transfected with optCPE-
GFP fusion protein. Strong cytotoxic effect, resulting in
62% reduction of cell viability, was measured 72 h after
optCPE-GFP gene transfer (Fig. 3d).
In addition to the previous described knock-in experi-
ments, we also performed knock-down experiments in
the human colon cancer cell lines HCT116 and SW480
by using short interfering RNA, targeting claudin-3 and
-4 to proof the important role of the claudins in the CPE
mediated effect. The down-regulation of both claudins
(siCldn3 + siCldn4) led to a significantly reduced respon-
siveness of the colon cancer cells towards recCPE treat-
ment and optCPE gene transfer compared to control
(siCo) treated cells, demonstrating specific activity of
CPE to its receptors claudin-3 and -4 (Additional file 2).
To prove the specific co-localization of CPE and
claudin-3, we analyzed Cldn-3-YFP expressing Sk-Mel5
cells after treatment with recCPE or after transfection
with the optCPE-GFP expressing vector by confocal
fluorescence microscopy. After external application of
recCPE, binding of the toxin in areas of strong Cldn-3-
YFP expression within the cell membrane and cytoplasm
was observed (Fig. 3e upper panel). Analysis of CPE-
distribution after transfection with optCPE-GFP fusion
protein expressing vector revealed a membranous bind-
ing of CPE and cytoplasmic CPE accumulation (Fig. 3e
lower panel).
Time lapse of CPE toxicity
Time lapse evaluation after recCPE treatment by live
fluorescence microscopy in Sk-Mel5 Cldn-3-YFP cells
revealed a rapid process of cell death starting at 20 min
after recCPE addition. This process continued with
swelling of treated cells, cell blebbing and size reduction
of nuclei (Fig. 3f ). To quantify the decrease in size nuclei
area was measured over a time period of 45 min. These
measurements showed significant (***P < 0.001) size re-
duction of 50%, indicative for rapid nuclear damage and
cell death (Additional file 3).
Claudin-3 and -4 expression in patient-derived colon
carcinoma xenografts
To extend the approach beyond the established in vitro
models to in vivo optCPE gene transfer application,
claudin-3 and -4 expression was analyzed in human
patient-derived colon carcinoma xenografts (PDX) at
protein level (Fig. 4a). We found claudin-3 and/or -4 ex-
pression in 26 of 27 analyzed tumors of which 19
showed high expression of both proteins. Only one
tumor (Co5735) did not express claudin-3 or -4. The im-
munohistochemistry confirmed Western blot data and
indicates mostly membranous localization as shown for
representative PDX tumors (Fig. 4b).
In vivo expression of CPE and antitumoral efficiency after
non-viral intratumoral CPE gene transfer
The intratumoral CPE expression was first analyzed after
non-viral intratumoral in vivo optCPE gene transfer jet
injection of the optCPE-GFP expressing vector (Fig. 4c).
Efficient expression of optCPE-GFP fusion protein was
determined 24 h and 48 h after gene transfer. The im-
munofluorescence revealed areas of strong optCPE-GFP
expression within tumor tissues (Fig. 4d), indicating a
successful in vivo optCPE gene transfer.
After optCPE-GFP jet-injection gene transfer (day 46
after tumor implantation), significant antitumoral activ-
ity by optCPE-GFP mediated cytotoxicity was observed
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in transfected Co7515 PDX-bearing mice. Tumor growth
inhibition, as measured by tumor volume, was signifi-
cant (*P = 0.0451) in optCPE-GFP transfected tumors
compared to vector transfected control group (Fig. 4e).
Evaluation of HE-stained sections of optCPE transfected
tumors revealed massive necrotic areas within the
tumors due to optCPE action (Fig. 4f ). In all animals no
systemic toxicities, such as body weight loss, diarrhea or
increase in body temperature were observed, which
strongly indicates safety of this gene therapeutic ap-
proach (Additional file 4). This is supported by the fact,
that analysis for potential appearance of CPE in the
Fig. 2 Cytotoxicity of CPE gene transfer in human colon carcinoma cells. a Time-dependent cytotoxicity of CPE after transfection with the pCpG-
optCPE (optCPE) and empty vector (e.v.). MTT cytotoxicity assay was performed 24, 48 and 72 h after transfection. All transfected colon cancer
cells reveal strong cytotoxic effects (P < 0.0001) mediated by optCPE 48 h after gene transfer. Sk-Mel5 cells were unaffected. Measurements were
done in triplicates and expressed as mean percent of untreated control. Bars: SD. Level of significance was calculated by 2way-ANOVA; * P < 0.05,
** P < 0.001, *** P < 0.0001. b Analysis of CPE release by optCPE transfected human colon carcinoma cell lines. Media of optCPE transfected cells
were harvested 48 h after transfection and analyzed by western blot. Representative blot shows released CPE within the media in all transfected
cells. c Analysis of biological activity of released optCPE. optCPE containing media were added once to respective non-transfected cell lines and
cytotoxicity was determined by MTT 72 h after application. SW620, SW480, HCT116 and CaCo-2 cells showed strong significant decrease in cell
viability, correlating with amount of released optCPE (see b). HT-29 cells released low amounts of optCPE protein (see b) after transfection and
cell viability was not reduced after application of optCPE containing medium. Columns represent mean percentage of untreated control cells.
Bars, SD. Measurements were performed in triplicates and levels of significance were calculated by Student’s t- test; *** P < 0.0001. d Analysis of
cytotoxic effect after repeated application of CPE containing medium in HT-29 cells. optCPE containing medium of optCPE transfected cells (see
b) was added twice a day at 5.4 ng CPE ml-1 (see Table 3) to non-transfected HT-29 cells. MTT assay was performed 72 h after treatment and
significant decrease of cell viability (P < 0.0001) was measured. Measurements were done in triplicates and expressed as mean percent of
untreated control. Bars: SD. Level of significance was calculated by Student’s t-test; *** P < 0.0001
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blood of the animals by ELISA revealed no shedding of
the toxin to the circulation (Additional file 5).
Discussion
Pore-forming CPE as effective cancer therapeutic
Genes coding for bacterial toxins have shown their
therapeutic potential for cancer treatment in cancer gene
therapy [10, 37–40]. Especially pore-forming toxins like
Streptolysin O from Streptococcus pyogenes and Clostrid-
ium perfringens enterotoxin (CPE) from Clostridium
perfringens are of increasing interest, of which CPE pos-
sesses high specificity in action [12, 13, 41]. The targeted
action of CPE is mediated by binding to claudin-3
and -4, which are frequently overexpressed in cancers.
This is in line with other studies, which show an up-
regulation of claudin-3 and -4 in colorectal cancers
compared to their expression in normal mucosa [26, 29].
In fact these findings render claudin-3 and -4 an attractive
target for selective therapy. In this study we demonstrated,
that colon cancer cells also overexpress claudin-3
and-4, which therefore represents the potential target
for CPE therapy.
CPE binding to the claudins results in rapid cell lysis
[42, 43]. The antitumoral effect of recombinant CPE
(recCPE) has been shown in several in vitro and in
vivo studies. It was demonstrated however, that the
therapeutic use of recCPE is restricted by the need
of repeated application to achieve an antitumoral
effect [29, 44–47].
This limitation can be overcome by gene therapeutic
use of CPE-expressing vectors for improved and
prolonged toxin action to treat cancers such as colon
carcinoma [11, 18, 45].
Selectivity of CPE-mediated rapid cytotoxicity
In this approach we demonstrated for the first time that
CPE was efficiently expressed in colon cancer cells in
vitro as well as in colon cancer PDX in vivo optCPE
gene transfer, which led to effective tumor cell lyses in
claudin-3 and -4 positive cells, whereas claudin-negative
cells remained unaffected [48]. Several publications have
characterized claudin-3 and -4 as natural and specific
receptors for CPE [49–52]. Here, sensitivity of colon
cancer cells towards external application of recCPE and
more importantly of gene transfected CPE was shown.
We demonstrated a direct correlation of claudinexpres-
sion, localization and CPE toxicity.
There is only one report about the use of CPE for can-
cer gene therapy [11], whereas other bacterial toxins,
such as Pseudomonas exotoxin, Diphteria toxin and
Streptolysin O, have already been analyzed regarding
their gene therapeutic use and antitumoral effects. After
transfection of Streptolysin O and Diphteria toxin ex-
pressing vectors, both toxins exerted toxic effects in
vitro and in vivo, but also led to side effects, as these
toxins act on non-tumor targets [8, 9, 12]. By con-
trast, CPE has the advantage of specific binding to
claudin-3 and -4, which is accessible at the cell surface
and potentially also in the cytoplasm of cancer cells.
Previously we established a translation optimized CPE
vector (optCPE), which combines both, target specificity
and efficient cytotoxicity [11]. Using the optCPE and
optCPE-GFP fusion protein in this approach, rapid tumor
destruction in vitro and in vivo was achieved after optCPE
gene transfer. In fact, the selectivity of CPE tumor cell
eradication was further supported by the use of the iso-
genic Sk-Mel5 cells, in which only the claudin-3 express-
ing cells were susceptible towards CPE action and claudin
negative cells remained unaffected. More importantly,
siRNA-mediated down-regulation of claudin-3 and -4
in colon cancer cells led to decreased responsiveness of
these cells towards CPE toxicity. This strengthens the im-
portance of the claudins for targeted action of CPE in
colon cancer.
Release of CPE and bystander effect
It is still unknown how intracellularly expressed CPE is re-
leased to bind the extracellular domains of the claudins.
Table 2 Transfection efficiency of the human cancer cell lines,
determined by transfer of the pEGFP vector and FACScan







Table 3 Quantification of CPE release into the cell culture
medium of empty vector or optCPE-transfected human colon
carcinoma cells (error values are S.D.)
Cell line Vector CPE ± SD [ng ml-1]
Sk-Mel5 e.v. 0
optCPE 46.92 ± 22.06
HCT116 e.v. 0
optCPE 231.67 ± 46.21
SW620 e.v. 0
optCPE 67.30 ± 1.33
SW480 e.v. 0
optCPE 80.51 ± 5.97
CaCo-2 e.v. 0
optCPE 16.50 ± 3.15
HT-29 e.v. 0
optCPE 5.40 ± 0.9
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Fig. 3 (See legend on next page.)
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CPE is naturally produced by the clostridium bacteria and
only liberated by lyses during bacterial sporulation [53,
54]. As we have described previously and observed in this
study, released CPE is present in the media of all trans-
fected cells, suggesting that it is liberated independently of
CPE-mediated cytotoxicity or claudin-3 and -4 expression,
as it was also released by the claudin-negative Sk-Mel5
cells [11]. This supports the concept of the bystander ef-
fect, as it contributes to the efficiency of gene therapy.
The bystander effect was seen during in vitro optCPE
gene transfer, as it eradicated up to 92% of colon carcin-
oma cells, although transfection efficiencies range only be-
tween 35 to 75%. The biological activity was further
proven as non-transfected cells treated with released CPE
containing media revealed strong cytotoxicity. Such effect
can be crucial for improved therapeutic efficiency, particu-
larly for in vivo optCPE gene transfer.
Time lapse of CPE toxicity
Additionally we demonstrated the process of cell death
after external application of recCPE by localization ana-
lysis and confirmed biological activity of released
optCPE, as cell death was initiated as early as 20 min
after treatment. Furthermore, this was validated by sig-
nificant decrease of nuclear size by 50%, which could be
caused by aggregation of chromatin during apoptosis, by
chromatin dissolution or nuclear fragmentation during
necrosis. In previous analyses for external therapeutic
application of recCPE both, necrosis and apoptosis were
reported, depending on the CPE doses used [25]. We
further showed in our previous study that the intracellu-
lar accumulation of CPE induced rapid release of cyto-
plasmic lactate dehydrogenase (LDH), activation of
caspases 3/7 in vitro and caused in vivo necrosis in CPE
transfected tumors [11].
CPE sensitivity of claudin-3 and -4 expressing patient derived
colon carcinoma xenografts (PDX)
The selective and efficient cytotoxic effect of CPE gene
transfer was proven for human colon cancer cell lines in
vitro. Our study extended the promising anticancer po-
tential of CPE gene therapy to in vivo optCPE gene
transfer scrutinization in a patient derived subcutaneous
xenograft model derived from a metastatic colorectal
tumor. By screening of 27 colon carcinoma PDX for
claudin-3 and/or -4, the clinical relevance of this ap-
proach was further supported, as 20 out of 27 PDX
models showed both, claudin-3 and claudin-4 expres-
sion, whereas 3 revealed the expression of only claudin-
3, suggesting, that binding of CPE can occur. We further
demonstrated the selective and efficient antitumoral ac-
tion of CPE gene therapy in the claudin-3 and -4 overex-
pressing PDX Co7515, where gross tumor necrosis of
the treated tumors was observed. This strongly indicates
the applicability of this suicidal gene therapy for the
treatment of colon carcinomas.
Conclusions
We report for the first time the successful tumor-
targeted CPE gene therapy for colon carcinoma in vitro
and in vivo optCPE gene transfer. This approach demon-
strates that CPE gene transfer could be a promising and
efficient option for a targeted suicide gene therapy of
claudin-3 and/or -4 expressing colon carcinoma.
The CPE gene therapy is of particular interest if ap-
plied locally to treat either unresectable residual cancer
tissue or to treat unresectable or refractory liver or lung
(See figure on previous page.)
Fig. 3 Specificity of CPE in the isogenic cell lines SK-Mel5 and SK-Mel5 Claudin-3-YFP a Western blot analysis for claudin-3-YFP gene expression in
Sk-Mel5 Cldn-3-YFP cells and no claudin-3 expression in Sk-Mel5 cells. b Representative immunofluorescence of Sk-Mel5, and Sk-Mel5 Cldn-3-YFP
cells. Claudin-3 negative cells were counterstained with Phalloidin (red). Nuclei were counterstained with Hoechst33343. Scale bar: 10 μm. The
image demonstrates specific claudin-3 expression (yellow) of Sk-Mel5 Cldn3-YFP cells. c Isogenic Sk-Mel5 and Sk-Mel5 Cldn-3-YFP cells were
treated with recCPE for 72 h at indicated concentrations. recCPE toxicity was determined by MTT cytotoxicity assay. Decreased cell viability
mediated by recCPE cytotoxicity is demonstrated in Sk-Mel5 Cldn-3-YFP cells, SK-Mel5 cells remained unaffected. All assays were performed in three
independent experiments and expressed as mean percent of untreated control. Bars: SD. Level of significance was calculated by 2way-ANOVA;
* P < 0.05, **; P < 0.001, *** P < 0.0001. The assay revealed highest specificity of recCPE mediated cytotoxicity by binding to claudin-3. d Cytotoxicity of
optCPE-GFP gene transfer in isogenic Sk-Mel5 pair and proof of claudin specificity. Isogenic cells were transfected with empty vector (e.v.) expressing
or optCPE-GFP expressing construct. MTT assay was performed 72 h after transfection. Controls are transfection reagent and e.v. transfected cells. All
assays were performed in three independent experiments and expressed as mean percent of untreated control. Bars: SD. Level of significance was
calculated by 1way-ANOVA, *** P < 0.0001. The assay demonstrates high cytotoxicity for optCPE-GFP expressing Sk-Mel5 Cldn3-YFP cells, which acts
selectively on claudin-3 cells, leaving claudin-negative Sk-Mel5 cells unaffected. e Representative images for co-localization of Cldn-3-YFP and CPE.
Upper panel represents Sk-Mel5 Cldn-3-YFP cells, incubated with recCPE (250 ng ml -1) for 30 min and counterstained with specific CPE antibody and
Alexa555 labeled secondary antibody; Cldn-3-YFP (green), recCPE (red) and co-localization of CPE/Cldn-3-YFP (yellow) is shown. Nuclei were counter-
stained with Hoechst 33343 (blue). Scale bar: 10 μm. Lower panel demonstrates Sk-Mel5 Cldn-3-YFP cells transfected with optCPE–GFP and fixed 24 h
later. Expressed Cldn-3-YFP (green), optCPE (red) and their co-localization (yellow) were detected (indicated by arrows). CPE was mainly located at the cell
membrane. Counterstaining of nuclei with Hoechst 33343 (blue). Scale bar: 20 μm. These images confirm co-localization and specificity of CPE binding
to claudin-3 as well as CPE accumulation within the cytoplasm. f Time-dependent cell death analysis after external application of recCPE (150 ng ml -1).
Sk-Mel5 Cldn-3-YFP cells were imaged for 45 min after recCPE addition. This process continued with swelling of treated cells, cell blebbing and size
reduction of nuclei. Cell nuclei were stained with Hoechst33343 (blue). Scale bar: 25 μm
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Fig. 4 Analysis of claudin-3 and -4 expression and CPE sensitivity in patient derived colon carcinoma xenografts. a Western blot analysis for
claudin-3 and claudin-4 expression, demonstrating highest expression of the claudins in colon cancer, since 26 of 27 analyzed tumors expressed
claudin-3 and/or -4. Only one tumor (Co5735) did not express one of the claudins. b Representative images of immunohistochemistry for
claudin-3 and -4 expression (brown staining) in the PDX tumors Co5735, Co7515*, Co7553A, Co7596 and Co7835, which correlated with protein
expression (see A). The claudin-negative PDX Co5735 did not show any specific staining, whereas membranous localization of claudin-3 and/or -4
was found within the other representative PDX models. c Representative scheme of non-viral in vivo gene transfer using the jet-injection.
d Intratumoral distribution of optCPE-GFP fusion protein expression 24 and 48 h after in vivo gene transfer of Co7515* tumors. Representative
immunofluorescence images revealed strong optCPE-GFP accumulation within the tissues (green). Tissue disruption and cell death can be already seen
after 24 h but strong areas of necrosis where detected after 48 h (see insets), indicating a successful gene transfer. Cell nuclei were counterstained with
Dapi (blue). Scale bar: 100 μm. e Inhibition of Co7515* PDX tumor growth after optCPE-GFP gene transfer. The vector-transfected tumors serve as
control. The in vivo optCPE-GFP gene transfer led to significant reduction in tumor growth (P = 0.0451); level of significance was determined by using
non-parametric t-test; bars, S.E.M. f Representative H&E staining of terminal tumor sections (day 63 after Co7515* PDX inoculation) show incidence of
massive necrotic areas in optCPE-GFP transfected tumors compared to vector control, indicating applicability of this gene therapy for colon carcinoma.
Scale bar: 100 μm
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metastasis of colorectal cancers. In fact, we did use in
our in vivo optCPE gene transfer experiment the
Co7515 PDX model, which highly expresses claudin-3
and -4 and is derived from lung metastasis of colon can-
cer. This provides some hint that such approach might
be of value for the local control of the disease. There-
fore, this strategy could be of particular value for treat-
ment of therapy-refractory tumors or metastases thereof.
Additional files
Additional file 1: Table S1. List of patient derived colon carcinoma
xenografts (PDX) and their primary origin. (XLSX 39 kb)
Additional file 2: Figure S1. Knockdown of claudin-3 and -4 leads to
reduced CPE activity in human colon cancer cells. a Sequences of used
short interfering RNA (siRNA) targeting claudin-3 and -4. b Western blot
analysis for claudin-3 and claudin-4 gene expression in human colon
cancer cell lines SW480 (left panel) and HCT116 (right panel) 72 h after
siRNA treatment, showing an efficient down-regulation of both with
two independent siRNA compared to control (siCo). c Specific toxin
responsiveness of claudin-3 and -4 down-regulated colon cancer cells.
72 h after siRNA transfection tumor cells were treated with recCPE at
indicated concentrations for another 72 h. The cytotoxicity was determined
by MTT assay and compared to siCo treated cells. A significantly reduced
responsiveness (*** P < 0.0001) was demonstrated in both colon cancer cell
lines, SW480 (left panel) and HCT116 (right panel). All assays were performed
in two independent experiments and are expressed as mean percent of
untreated control. Bars: SD. Level of significance was calculated by 2way-
ANOVA (Bonferroni posttest). b Cytotoxicity of optCPE gene transfer in
siRNA treated colon cancer cells and proof of claudin specificity. The
siCldn3 + siCldn4 treated SW480 and HCT116 cells were transfected with
optCPE construct 72 h after siRNA treatment. MTT assay was performed 72 h
after CPE treatment and a significantly reduced CPE mediated cytotoxicity
was observed in down-regulated SW480 (left panel) and also in HCT116
(right panel) cells compared to siCo treated cells. All assays were performed
in two independent experiments and expressed as survival in optical
density [OD]. Bars: SD. Level of significance was calculated by nonparametric,
unpaired students t-test, *** P < 0.0001. Both assays demonstrate high
selectivity of CPE on claudin-3 and -4 as down-regulated cells remain
unaffected. (JPG 600 kb)
Additional file 3: Figure S2. Quantification of change in nuclear size
by CPE treatment. Size of nuclei was measured after recCPE application
over a time period of 45 min. The data show significant reduction in
nuclear size, indicating rapid cell death mediated by recCPE. Area of
three nuclei were calculated every 5 min by Imaris Cell 7.6. Value
represents mean, errors are given as S.D. (JPG 111 kb)
Additional file 4: Figure S3. Influence of optCPE in vivo gene transfer
on body weight. Body weight of Co7515* PDX bearing mice was
measured during tumor growth inhibition. In all animals no systemic
toxicities, such as body weight loss, were observed, which strongly
indicates the safety of this gene therapeutic approach. (JPG 283 kb)
Additional file 5: Table S2. Quantification of CPE shedding into blood
circulation of control-, vector- or optCPE-treated animals. (XLSX 38 kb)
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